Supplemental material for "Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)"
收藏DataCite Commons2025-04-01 更新2025-04-16 收录
下载链接：
https://data.mendeley.com/datasets/j5gd4ndd2g
下载链接
链接失效反馈官方服务：
资源简介：
Supplemental material for Lebwohl, et al., "Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)," J Am Acad Dermatol, 2020
提供机构：
Mendeley
创建时间：
2020-09-16
